Polyethylene glycol-modified urate oxidase
Patent Information
- Application Number
- JP2023210531
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-05-10
- Filing Date
- 2023-12-13
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2040-05-08
AI Technical Summary
Current treatments for hyperuricemia and gout, such as allopurinol and recombinant uricase drugs, face challenges with immunogenicity and allergic reactions, limiting their long-term efficacy and suitability for subcutaneous administration.
Polyethylene glycol (PEG) modification of urate oxidase at specific lysine sites reduces immunogenicity and enhances stability, allowing for intramuscular injection and sustained efficacy.
The PEG-modified urate oxidase maintains enzyme activity while significantly reducing immunogenicity, enabling longer-lasting uric acid reduction in the body and safer, more effective treatment of hyperuricemia and gout.
Smart Images

Figure 2024037877000001
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of biomedicine, in particular the present invention relates to polyethylene glycol modified urate oxidase, more particularly the present invention relates to polyethylene glycol modified urate oxidase, pharmaceutical combinations, pharmaceutical uses of polyethylene glycol modified urate oxidase and methods for reducing the immunogenicity of urate oxidase. [Background technology]
[0002] Gout is a disease caused by a disorder of purine metabolism, and its clinical characteristic is hyperuricemia, which causes the deposition of uric acid salts under the skin, in the joints, and in the kidneys, resulting in the formation of gouty tophi. Purines in the human body undergo a series of changes, and the final product formed is uric acid, which causes hyperuricemia when the blood uric acid concentration exceeds 70 mg / L. 5% to 12% of patients with hyperuricemia may develop gout. In blood and synovial fluid, the concentration of sodium urate reaches saturation, forming microcrystals of sodium urate salt, which may cause gouty arthritis. Over time, chronic hyperuricemia may also produce destructive crystalline uric acid deposits around joints, soft tissues, and certain organs, causing diseases such as gouty acute arthritis, gouty chronic arthritis, and joint deformity. Kidney damage is considered to be the second most common clinical manifestation of gout. The gradual nature of chronic hyperuricemia results in the deposition of urate salts in the medulla, renal tubules and renal interstitium, causing local irritation and an inflammatory response, termed chronic urate nephropathy. Patients with severe hyperuricemia (e.g., those with certain malignant tumors, especially leukemia and lymphoma) may experience large amounts of uric acid being deposited in the renal collecting duct, renal pelvis, renal calyx and ureters in a short period of time, causing luminal obstruction and urinary retention, leading to acute renal failure (urate nephropathy).
[0003] In recent decades, with the improvement of people's quality of life and changes in diet and lifestyle, the number of gout patients has been increasing year by year, along with the increase in the intake of high-protein and high-purine foods. In Europe, the number of gout patients has nearly doubled in the past 20 years. Currently, the incidence of hyperuricemia and gout in our country has increased to about 2-3%. When no clinical symptoms of hyperuricemia appear, dietary control is sufficient, and when clinical symptoms caused by it appear, drug treatment is required. The usual treatments currently used in clinical practice include analgesics and anti-inflammatory drugs such as colchicine, buprofen, and naproxen, which are mainly used to control acute attack symptoms of gouty arthritis and relieve local joint pain, swelling, and inflammation in the joints, uricosurics that promote the excretion of uric acid such as probenicid, sulfinpyrazone, and benzbromarone (which are ineffective when renal function is reduced), and drugs that inhibit uric acid synthesis such as allopurinol. Allopurinol is the main treatment for patients suffering from tophaceous gout, renal failure, leukemia, and certain genetic diseases, and inhibits xanthine oxidase, preventing hypoxanthine and xanthine from being converted into uric acid, which is gradually oxidized in the human body to produce oxipurinol, which is easily soluble in water, and is excreted in the urine. However, all conventional treatments are difficult to cure chronic gout patients who have formed gouty tophi. After taking the above drugs for a long time, patients will inevitably suffer from complications such as leukopenia, cardiac dysfunction, liver dysfunction, gastrointestinal irritation, diabetes due to aplastic anemia, and gout.
[0004] Human hyperuricemia is associated with the mutation and inactivation of the uricase gene during human evolution; the mutation introduces a premature stop codon into the coding sequence of the human uricase gene (Wu X, Lee CC, Muzny DM, Caskey C T. Proc Natl Acad SciUSA. 1989. 86: 9412-9416.), so that humans cannot synthesize active uricase by themselves, and as a result, human purine degradation metabolism is terminated to uric acid (Wu X, Muzny DM, Lee CC, Caskey C TJ Mol Evol. 1992. 34: 78-84.). Active uricase in the hepatic peroxisomes of non-human primates and other mammals can convert the less soluble urate (~11 mg / 100 ml water) to the more soluble allantoin (~147 mg / 100 ml water), which is more effectively excreted by the kidney (Wortmann RL, Kelley W N. Kelley's textbook of rheumatology (6th). 2001: 1339-1376). In Europe and the USA, uricase prepared by Aspergillus flavus (Uricozyme) has been used for more than 10 years to treat severe hyperuricemia associated with tumor chemotherapy (Zittoun R, Dauchy F, Teilaud C, Barthelemy M, Bouchard P. Ann Med Interne. 1978. 127: 479-482.). The recombinant Aspergillus flavus uricase drug ELITEK, developed by the French company Sanofi and produced by fermentation of brewer's yeast, was approved by the FDA in 2002 for the short-term treatment of severe hyperuricemia caused by cancer chemotherapy (Pui CH, Relling MV, Lascombes F, Harrison P L, Struxiano A et al. Leukemia. 1997.11:1813-1816.), and at the same time, it has been demonstrated that injection of ELITEK can also reduce the volume of gouty tophi (Potaux L, Aparicio M, Maurel C, Ruedas ME, Mart in C L. Nouv Presse Med. 1975.4:1109-1112.).In September 2010, PEG-modified recombinant porcine uricase (Pegloticase), manufactured by the US company Savient, was approved by the FDA for use in the treatment of refractory gout. However, because it does not resolve the issue of immunogenicity, it is ineffective in approximately 50% of patients in clinical use.
[0005] Uricase (EC 1.7.3.3) is widely present in microorganisms (Bacillus fastidiosus, Candida monocytogenes, Aspergillus flavus), plants (soybean, chickpea) and animals (pig, cow, dog, baboon) (Suzuki K, Sakasegawa S, Misaki H, Sugiyama M. J Biosci Bioeng. 2004.98 :153-158), and in the presence of oxygen, it can catalyze the oxidation of uric acid to allantoin and release carbon dioxide (Retailleau P, Colloc'h, Denis V, Francoise B. Acta Cryst D. 2004.60 :453-462.).
[0006] Active uricase is a tetrameric protein composed of identical subunits, each of which has a molecular weight of about 34 kD and consists of 301-304 amino acids. The pH value of the highest enzymatic activity of uricase in each solution is 8.0 (Bayol A et al.Biophys Chem.1995.54 :229-235.). Among all currently known sources of uricase, the highest activity is from Aspergillus flavus, reaching 27 IU / mg, followed by Bacillus fastidiosus, whose activity remains at 13 IU / mg (Huang SH, Wu T K.Eur J Biochem.2004.271:517-523.). In addition, uricase derived from legumes has activity of only 2-6 IU / mg, and after recombinant expression, uricase derived from mammals has activity of 5 IU / mg in pigs and only 1 IU / mg in baboons (Michael H, Susan JK 2006. US7056713B1), and human uricase has no activity.
[0007] For human application, the high activity of microbial uricase and the low immunogenicity of mammalian uricase make these two uricase sources the current research hotspots in the development and application of recombinant uricase. However, the homology between uricase from Aspergillus flavus and the putative human uricase is less than 40% (Lee CC, Wu X, Gibbs RA, Cook RG, Muzny DM, Caskey C T. Science. 1988. 239: 1288-1291.), the human body is prone to produce anti-uricase antibodies, the efficacy of Aspergillus flavus uricase is rapidly weakened, and at the same time, it can cause severe allergic reactions and cannot be used for long-term treatment.
[0008] Therefore, urate oxidase-based treatments for hyperuricemia require further development and improvement. Summary of the Invention
[0009] This application is based upon the inventors' discovery and appreciation of the following facts and problems.
[0010] Active urate oxidase is a homotetrameric protein, one-third of the amino acids are strongly hydrophobic amino acids, and the tetrameric proteins easily aggregate to form octamers and larger polymers. Molecules with molecular weights above 100 kDa can effectively induce the body to produce an immune response, and the molecular weight of unmodified urate oxidase protein reaches 140 kDa, and the larger molecular weight multimeric uricase has higher immunogenicity. The human body is prone to producing anti-uricase antibodies, which quickly weakens its efficacy, and at the same time, causes severe allergic reactions, making it unusable for long-term treatment. Covalent modification of proteins with PEG has been proven to reduce protein immunogenicity, increase protein solubility, and extend protein half-life.
[0011] Duke University and Savient have conducted a chimeric uricase study of pig and baboon origin (Michael H, Susan JK2006.US7056713B1). The method of this study is to modify the ε-amino group of the lysine residue of uricase from pigs with methoxy-containing polyethylene glycol (10KDa-mPEG-NPC) under conditions that do not significantly reduce the enzyme activity (the resulting modified product is Pegloticase), which is the first to achieve the goal of treating intractable gout in humans. The inventors found that the above research results could not completely solve the problem of drug-induced immunogenicity, and found that clinical subjects lost the therapeutic effect of uricase after multiple injections. The inventors speculated that this may be related to the excessive molecular weight of the pegloticase protein (when 10kd PEG is used, the molecular weight of pegloticase is 540kDa). At the same time, pegloticase is not suitable for injection, but is suitable for intravenous injection, which reduces the subjects' willingness to use it for a long time, and further severely limits its clinical application. Up to now, there is no long-acting urate oxidase drug that has lower immunogenicity and can be injected subcutaneously.
[0012] The present invention aims to solve at least to some extent one of the technical problems in the related art.
[0013] In a first aspect of the present invention, the present invention provides a polyethylene glycol-modified urate oxidase. According to an embodiment of the present invention, the urate oxidase is modified with a polyethylene glycol-modified urate oxidase having an amino acid site, T 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272, K 285 , K 291 , K 293 At least 11 of the amino acid sites of the polyethylene glycol-modified urate oxidase of the present application are modified with PEG. It is necessary to explain that the term "urate oxidase" described in this application should be understood in a broad sense, which refers to a mixture of urate oxidases produced in the same batch in actual manufacturing practice. The inventors have found that, compared with similar drugs already on the market, at least 11 of the amino acid sites of the polyethylene glycol-modified urate oxidase of the present application are modified with PEG, which can greatly improve the stability of urate oxidase in vivo and reduce its immunogenicity under the premise of maximally ensuring the activity of the enzyme, and the efficacy in vivo after intramuscular injection can reach the same efficacy in vivo after injection of similar drugs already on the market.
[0014] According to an embodiment of the present invention, the urate oxidase may further include at least one of the following additional technical features: According to an embodiment of the present invention, K 30 , K 35 , K 222 and K 231 At least one, two, three or all of the four lysine sites of the ribozyme have a PEG modification.
[0015] According to an embodiment of the present invention, the molecular weight of the polyethylene glycol for PEG modification is not more than 6KD. The inventors have found that by modifying with polyethylene glycol having a molecular weight of 6KD or less, the long-term effect of the obtained urate oxidase in the body can be improved, and the excessive molecular weight does not cause serious anti-PEG antibody production, that is, the immunogenicity can be further reduced.
[0016] According to an embodiment of the present invention, the polyethylene glycol has a monomethoxy group or a hydroxyl group.
[0017] According to an embodiment of the present invention, the polyethylene glycol is a linear or branched structure.
[0018] According to an embodiment of the present invention, the polyethylene glycol and the urate oxidase are bonded via an amide bond.
[0019] According to an embodiment of the present invention, the polyethylene glycol is a modified polyethylene glycol, and the modifying group of the modified polyethylene glycol includes at least one selected from N-hydroxysuccinimide, N-hydroxysuccinimide carbonate, N-hydroxysuccinimide acetate, N-hydroxysuccinimide propionate, N-hydroxysuccinimide butyrate, N-hydroxysuccinimide succinate, and p-nitrobenzene carbonate.
[0020] According to an embodiment of the present invention, the modifying group of the modified polyethylene glycol is N-hydroxysuccinimide propionate.
[0021] According to an embodiment of the present invention, the amino acid sites are located based on the amino acid sequence shown in SEQ ID NO:1. TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDUVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGI KDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL(SEQ ID NO:1).
[0022] According to an embodiment of the present invention, the urate oxidase is an amino acid sequence as set forth in SEQ ID NO:1-7, or a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity compared to SEQ ID NO:1-7, or a polypeptide having one or more amino acid substitutions, deletions and / or additions compared to SEQ ID NO:1-7. MAHYRNDYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYLHGDNSDIVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIH SGIKDLKVLKTTQSGFEGFIKDQFTTLEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGRITGTVKRKLTSRL(SEQ ID NO:2). MYKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYVYGDNSDIIPTDTIKNTVHVLAKFKGIKSIETFAMNICEHFLSSFNHVIRAQVYVEEVPWKRFEKNGVKHVHAFIHNPTGTHFCEVEQMRSGPPVIHSGI KDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATKVYCKWRYHQGRDVDFEATWDTVRDIVLEKFAGPYDKGEYSPSVQKTLYDIQVHSLSRVPEMEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL(SEQ ID NO:3). MAHYHNDYKKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYVYGDNSDIIPTDTIKNTVHVLAKFKGIKSIETFAMNICEHFLSSFNHVIRAQVYVEEVPWKRFEKNGVKHVHAFIHNPTGTHFCEVEQMRSGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATKVYCKWRYHQGRDVDFEATWDTVRDIVLEKFAGPYDKGEYSPSVQKTLYDIQVHSLSRVPEMEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGRITGTAKRKLASKL(SEQ ID NO:4)。 MAHYHNDYQKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLNSRREYLHGDNSDIIPTDTIKNTVQVLAKFKGIKSIETFAMNICEHFLSSFNHVIRVQVYVEEVPWKRFEKNGVKHVHAFIHTPTGTHFCEVEQLRSGPPVIHSGIKDLKVLKTTQSGFEGFLKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWEAVRGIVLKKFAGPYDKGEYSPSVQKTLYDIQVLSLSQLPEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGRITGTVKRKLTSRL(SEQ ID NO:5)。 MAHYHNDYKKNDEVEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYLHGDNSDIIPTDTIKNTVHALAKFKGIKSIEAFAVNICQHFLSSFNHVIRTQVYVEEIPWKRLEKNGVKHVHAFIHTPTGTHFCEVEQLRSGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFAAQVYCKWRYHQCRDVDFEATWDTIRDVVLEKFAGPYDKGEYSPSVQKTLYDIQVVSLSQVPEIDDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL(SEQ ID NO:6)。 MADYHNNYKKNDELEFVRTGYGKDMVKVLHIQRDGKYHSIKEVATSVQLTLSSKKDYLHGDNSDIIPTDTIKNTVHVLAKFKGIKSIEAFGVNICEYFLSSFNHVIRAQVYVEEIPWKRLEKNGVKHVHAFIHTPTGTHFCEVEQLRSGPPVIH SGIKDLKVLKTTQSGFEGFIKDQFTTLEVKDRCFATQVYCKWRYHQCRDVDFEATWGTIRDLVLEKFAGPYDKGEYSPSVQKTLYDIQVLSLSRVPEIEDMEISLPNIHYFNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL(SEQ ID NO:7).
[0023] The amino acid sequence shown in SEQ ID NO:1 is the amino acid sequence of a chimeric uricase derived from pig and baboon (pig-baboon), the amino acid sequence shown in SEQ ID NO:2 is the amino acid sequence of a urate oxidase derived from pig, the amino acid sequence shown in SEQ ID NO:3 is the amino acid sequence of a chimeric urate oxidase derived from dog and baboon (canine-canine), the amino acid sequence shown in SEQ ID NO:4 is the amino acid sequence of a urate oxidase derived from dog, the amino acid sequence shown in SEQ ID NO:5 is the amino acid sequence of a urate oxidase derived from cow, the amino acid sequence shown in SEQ ID NO:6 is the amino acid sequence of a monkey urate oxidase, and the amino acid sequence shown in SEQ ID NO:7 is the amino acid sequence of a baboon urate oxidase.
[0024] As a matter of clarification, the positioning of lysines in the present application is based on the amino acid sequence shown in SEQ ID NO:1, e.g., K 4refers to the lysine at position 4 based on the amino acid sequence set forth in SEQ ID NO:1. Uricase having an amino acid sequence set forth in SEQ ID NO:1-7 or a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity to SEQ ID NO:1-7 or a polypeptide having one or more amino acid substitutions, deletions and / or additions to SEQ ID NO:1-7 have structural homology, and one of skill in the art can determine by sequence comparison a T-terminal sequence on SEQ ID NO:2-7 or a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity to SEQ ID NO:1-7 or a polypeptide having one or more amino acid substitutions, deletions and / or additions to SEQ ID NO:1-7. 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 The corresponding site is determined, and PEG modification is then performed at the corresponding site of the polypeptide, thereby realizing the advantages of the polyethylene glycol-modified urate oxidase of the present application having low immunogenicity, high stability in vivo, and suitable for intramuscular injection. The sequence comparison method is a common method used by those skilled in the art, which compares the sequence identity of isozymes with different sequence origins, and although the sequence length may differ between different sequences due to mutations, deletions, etc., those skilled in the art can determine the identity between different sequences by sequence comparison.
[0025] For example, according to an embodiment of the present invention, the sequence shown in SEQ ID NO:2 is a nucleotide sequence similar to that shown in SEQ ID NO:1. 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 The site corresponding to the site is M 1 , K 9 , K 10 , K 36 , K 41 , K 82 , K 85 , K 103 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 297 , K 299 The sequence shown in SEQ ID NO:3 corresponds to the sequence shown in SEQ ID NO:1 at a position corresponding to M 1 , K 3 , K 29 , K 34 , K 75 , K 78 , K 111 , K 115 , K 119 , K 151 , K 178 , K 221 , K 230 , K 265 , K 271 , K 284 , K 290 , K 292The sequence shown in SEQ ID NO:4 corresponds to the sequence shown in SEQ ID NO:1, and the corresponding site is M 1 , K 9 , K 10 , K 36 , K 41 , K 82 , K 85 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 297 , K 299 The sequence shown in SEQ ID NO:5 corresponds to the sequence shown in SEQ ID NO:1, and the corresponding site of the sequence shown in SEQ ID NO:5 corresponds to the sequence shown in SEQ ID NO:1, 1 , K 10 , K 36 , K 41 , K 82 , K 85 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 297 , K 299 The sequence shown in SEQ ID NO:6 corresponds to the sequence shown in SEQ ID NO:1, and the corresponding site of the sequence shown in SEQ ID NO:6 corresponds to the sequence shown in SEQ ID NO:1, 1 , K 9 , K 10 , K 36 , K 41 , K 82 , K 85 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 291 , K 297 , K 299The sequence shown in SEQ ID NO:7 corresponds to the sequence shown in SEQ ID NO:1, and the corresponding site of the sequence shown in SEQ ID NO:7 corresponds to the sequence shown in SEQ ID NO:1, 1 , K 9 , K 10 , K 36 , K 41 , K 82 , K 85 , K 118 , K 122 , K 126 , K 158 , K 185 , K 228 , K 237 , K 272 , K 278 , K 291 , K 297 , K 299 Through experiments, the inventors have found that after PEG modification occurs at at least 11 sites corresponding to the amino acid sequences shown in SEQ ID NO:2-7, the resulting PEG-modified urate oxidase has the advantages of low immunogenicity, high stability in the body, and suitable for intramuscular injection.
[0026] In a second aspect of the present invention, the present invention provides a polyethylene glycol-modified urate oxidase. According to an embodiment of the present invention, the relative percentage of peak area reduction of at least 11 predetermined peptide segments in the peptide map of the polyethylene glycol-modified urate oxidase compared with the peptide map of the urate oxidase not modified with polyethylene glycol is 75% or more, preferably 80% or more, more preferably 90% or more. The polyethylene glycol-modified urate oxidase according to the embodiment of the present invention has the advantages of low immunogenicity, high stability in the body, and suitable for intramuscular injection.
[0027] According to an embodiment of the present invention, the polyethylene glycol-modified urate oxidase may further include at least one of the following additional technical features: According to an embodiment of the present invention, the peptide map of the polyethylene glycol-modified urate oxidase has the peak area decreasing peptide segments shown in Table 5.
[0028] According to an embodiment of the present invention, the peptide map of the polyethylene glycol-modified urate oxidase is shown in FIG. 6 or FIG.
[0029] In a third aspect of the present invention, the present invention provides a pharmaceutical combination. According to an embodiment of the present invention, the pharmaceutical composition comprises the above-mentioned urate oxidase. The pharmaceutical composition according to an embodiment of the present invention has the advantages of low immunogenicity, high stability in the body, and suitable for intramuscular injection, and can be used for the treatment or prevention of hyperuric acid-related diseases.
[0030] According to an embodiment of the present invention, the pharmaceutical composition further comprises at least one of the following additional technical features: According to an embodiment of the present invention, the pharmaceutical composition further comprises other drugs for treating or preventing hyperuric acid-related diseases.
[0031] In a fourth aspect of the present invention, the present invention provides a use of the aforementioned urate oxidase or the aforementioned pharmaceutical composition in the preparation of a medicament for treating hyperuric acid-related diseases and reducing the level of uric acid in biological fluids of a subject in need thereof. The urate oxidase according to the embodiment of the present invention has the advantages of low immunogenicity, high stability in the body, and suitability for intramuscular injection, and has significant advantages in the treatment of hyperuric acid-related diseases.
[0032] According to an embodiment of the present invention, the above-mentioned application may further include at least one of the following additional technical features: According to an embodiment of the present invention, the hyperuric acid related disease includes diseases selected from chronic hyperuricemia, gout, kidney disease, hyperuricemia arthritis, kidney stones, gouty tophi, hypertension, diabetes, hypertriglyceridemia, metabolic syndrome, coronary heart disease, atherosclerosis, and hyperuricemia due to cancer chemotherapy.
[0033] According to an embodiment of the present invention, the biological fluid is urine or blood.
[0034] In a fifth aspect of the present invention, the present invention provides a method for reducing the immunogenicity of urate oxidase. According to an embodiment of the present invention, the method comprises: 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 and generating PEG modification on at least 11 of the urate oxidases. According to the method of the embodiment of the present invention, the immunogenicity of urate oxidase can be effectively reduced, and the obtained urate oxidase has higher safety in the body and a longer lasting effect.
[0035] According to an embodiment of the present invention, the above method may further include at least one of the following additional technical features: According to an embodiment of the present invention, the K 30 , K 35 , K 222 , K 231 At least one, at least two, at least three or four of the four lysine sites are PEG-modified.
[0036] According to an embodiment of the present invention, the molecular weight of the polyethylene glycol for PEG modification does not exceed 6 KD.
[0037] According to an embodiment of the present invention, the polyethylene glycol is a modified polyethylene glycol.
[0038] According to an embodiment of the present invention, the modifying group of the modified polyethylene glycol is N-hydroxysuccinimide.
[0039] According to an embodiment of the present invention, the amino acid site is located in the amino acid sequence shown in SEQ ID NO:1.
[0040] According to an embodiment of the present invention, the urate oxidase has an amino acid sequence as shown in SEQ ID NO:1-7 or a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identity to SEQ ID NO:1-7, or a polypeptide having one or more amino acid substitutions, deletions and / or additions to SEQ ID NO:1-7.
[0041] It is understandable that the technical effects of the additional technical features of the aforementioned polyethylene glycol-modified urate oxidase also apply to the additional technical features of the aforementioned method for reducing the immunogenicity of urate oxidase according to an embodiment of the present invention, and the additional technical features of the aforementioned method for reducing the immunogenicity of urate oxidase according to an embodiment of the present invention will not be described again here. [Brief description of the drawings]
[0042] [Figure 1] FIG. 2 shows PHC physical and chemical reference materials-SEC-HPLC-UV detection diagrams according to an embodiment of the present invention. [Diagram 2] FIG. 2 shows PHC physical and chemical reference materials-SEC-HPLC-RI detection diagrams according to an embodiment of the present invention. [Diagram 3] FIG. 2 is a PEG reference material-SEC-HPLC-RI detection diagram according to an embodiment of the present invention. [Figure 4] FIG. 2 shows SEC-HPLC-UV detection of PU5 modified products according to an embodiment of the present invention. [Diagram 5] FIG. 2 shows SEC-HPLC-RI detection of PU5 modified products according to an embodiment of the present invention. [Figure 6]FIG. 11 is a comparison of PHC and PU5 using double digestion with Lys-c and trypsin, respectively, according to an embodiment of the present invention. [Figure 7] FIG. 1 is a diagram of PU5 Lys-C digestion according to an embodiment of the present invention. [Figure 8] 1 shows serum uric acid levels after intramuscular administration of different dosages to model rats according to an embodiment of the present invention. [Figure 9] FIG. 1 is a graph showing the scores of kidney damage, necrosis and inflammation according to an embodiment of the present invention. [Figure 10] FIG. 1 shows average blood concentration-time curves for each group after a single intravenous injection of an injection solution of the same dose (1.0 mg / kg) of Pegloticase and polyethylene glycolated uricase to SD rats according to an embodiment of the present invention. [Figure 11] FIG. 2 is a graph showing the average blood concentration-time curves of each group after a single intramuscular injection of an injection solution of Pegloticase and polyethylene glycolated uricase of different doses into SD rats according to an embodiment of the present invention. [Figure 12] FIG. 2 is a graph showing the average blood concentration-time curves of each group after a single intramuscular injection of different doses of polyethylene glycol-modified uricase injection solution to SD rats according to an embodiment of the present invention. [Figure 13] FIG. 1 shows the average blood uric acid level-time curves for each group at different times after a single intramuscular / intravenous injection of different doses of Pegloticase and polyethylene glycolated uricase injection solution to SD rats according to an embodiment of the present invention. [Figure 14] FIG. 1 shows average blood concentration-time curves in male and female rats after the same dose (1.0 mg / kg) of Pegloticase and polyethylene glycolated uricase injection was administered intravenously to SD rats in accordance with an embodiment of the present invention on the first day (Day 1). [Figure 15] FIG. 1 shows average blood concentration-time curves in male and female rats after the final (Day 22) intravenous injection of the same dose (1.0 mg / kg) of Pegloticase and polyethylene glycolated uricase injection solution to SD rats according to an embodiment of the present invention. [Figure 16]FIG. 1 shows average blood concentration-time curves in male and female SD rats after the first (Day 1) intramuscular injection of the same dose (1.0 mg / kg) of Pegloticase and polyethylene glycolated uricase injection solution according to an embodiment of the present invention. [Figure 17] FIG. 1 shows average blood concentration-time curves in male and female SD rats after the final (Day 22) intramuscular injection of the same dose (1.0 mg / kg) of Pegloticase and polyethylene glycolated uricase injection solution in accordance with an embodiment of the present invention. [Figure 18] FIG. 1 is a graph showing the average blood uric acid level vs. time curve at different times after multiple intravenous injections of Pegloticase and polyethylene glycolated uricase injections into SD rats according to an embodiment of the present invention. [Figure 19] FIG. 2 is a graph showing the average blood uric acid level vs. time curve at different times after multiple intramuscular injections of Pegloticase and polyethylene glycolated uricase injections into SD rats according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0043] Hereinafter, the embodiments of the present invention will be described in detail, and examples of the embodiments are shown in the drawings. The embodiments described below with reference to the drawings are illustrative and are used to interpret the present invention, but should not be understood as limiting the present invention.
[0044] An object of the present invention is to provide a novel polyethylene glycol-modified urate oxidase.
[0045] Another object of the present invention is to provide a method for effectively reducing the immunogenicity of urate oxidase, which can effectively reduce the immunogenicity of urate oxidase and improve the safety and stability of urate oxidase in the body.
[0046] Another objective of the present invention is to provide an application of the polyethylene glycol oxyuricase conjugate obtained above, which can achieve the effect of sustained and significant reduction of blood uric acid level in the body, and can be used for the treatment of hyperuricemia and gout.
[0047] In one aspect of the present invention, there is provided a polyethylene glycol-modified urate oxidase.
[0048] As used herein, the terms "urate oxidase" and "uricase" are used interchangeably and refer to a class of enzymes according to the present invention that catalyze and oxidize uric acid to produce allantoin and hydrogen peroxide. The terms "urate oxidase analog", "uricase analog", and "uricase derivative" are interchangeable, and based on the fact that uric acid oxidase retains the activity of specifically catalyzing and converting uric acid into allantoin and hydrogen peroxide, the protein structural sequence of uric acid oxidase can be modified in structure, such as by substituting, deleting, or adding some amino acids, thereby achieving, but not limited to, the reduction of immunogenicity in this example, the improvement of protein stability, and the promotion of further polyethylene glycol modification.
[0049] The urate oxidase is not particularly limited and may be urate oxidase of any origin and its urate oxidase analogues, and representative examples include, but are not limited to, those derived from mammals, microorganisms, plants, etc.
[0050] In another preferred embodiment, the urate oxidase and its analogues are derived from mammals, and preferably have the amino acid sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, more preferably SEQ ID NO:1.
[0051] The urate oxidase from different species according to the present invention can be obtained by various methods including, but not limited to, natural extraction, chemical synthesis, genetically engineered recombinant expression, and the like.
[0052] In another preferred embodiment, the urate oxidase is recombinantly expressed in a host cell using recombinant techniques to express the coding sequence of the urate oxidase protein sequence (SEQ ID NO:1).
[0053] In another preferred example, the bacteria is prepared by constructing a recombinant expression strain using E. coli or yeast as a host, and more preferably, recombinant expression is carried out using E. coli as a host bacterium.
[0054] As used herein, the polyethylene glycol urate oxidase described in the present invention is obtained by covalently modifying urate oxidase with polyethylene glycol. The polyethylene glycol (PEG) refers to a mixture of ethylene oxide condensation polymer and water, and is represented by the general formula H(OCH2CH2)nOH, which is a hydrophilic polymer with neutral pH, non-toxicity, and high water solubility, and exhibits a linear or branched structure. Due to the non-toxicity and good biocompatibility of PEG, the FDA has currently approved the market launch of multiple kinds of PEG-modified recombinant protein drugs, proving that PEG can be used to reduce protein immunogenicity, increase protein solubility, and extend protein half-life. To bind PEG to a protein, one or more ends of PEG need to be activated, and the corresponding modification groups, such as amino groups, sulfhydryl groups, carboxyl groups, or hydroxyl groups, can be selected and activated according to the modified target protein.
[0055] In another preferred embodiment, the site for PEG modification of urate oxidase and uricase analogs of the present invention is the ε-amino group of lysine residue, but a small amount of the α-amino group of N-terminal lysine residue is modified. Urate oxidase is covalently linked to the modifying group of PEG via amino lipid bond, secondary amino bond or amide bond, preferably, polyethylene glycol molecule is bonded to urate oxidase to form amide bond, the modifying group of polyethylene glycol includes but is not limited to N-hydroxysuccinimide, etc., including but not limited to N-hydroxysuccinimide (NHS), N-hydroxysuccinimide carbonate (SC), N-hydroxysuccinimide acetate (SCM), N-hydroxysuccinimide propionate (SPA), N-hydroxysuccinimide butyrate (SBA), succinic acid N-hydroxysuccinimide (SS), etc., and the blocking group of polyethylene glycol includes but is not limited to monomethoxy group, ethoxy group, glucose or galactose sugar, preferably monomethoxy group.
[0056] In other preferred examples, the polyethylene glycol may be linear or branched.
[0057] In another preferred embodiment, the relative molecular weight of polyethylene glycol used in polyethylene glycol urate oxidase is 6KD or less, preferably 1KD-5KD, more preferably 2KD, 5KD, and most preferably 5KD. As a matter of clarification, the "relative molecular weight of polyethylene glycol" described in this application refers to the relative molecular weight of polyethylene glycol without modification groups and has the general meaning in the art, and after PEG is activated by an activating group, the total relative molecular weight is slightly larger than 5KD, such as within the range of 5KD+10%.
[0058] In another preferred embodiment, the polyethylene glycol-modified urate oxidase has the following characteristics: (1) The amino acid site in urate oxidase, T 1 , K 3 , K4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 At least 11 of them have PEG modifications. (2) On average, one urate oxidase monomer molecule is bound to 11 to 13 polyethylene glycol molecules. (3) K located in Seq ID NO:1 urate oxidase sequence 30 and / or K. 35 , and K 222 and / or K. 231 is modified by a polyethylene glycol bond. (4) Polyethylene glycol urate oxidase has lower immunogenicity in the body.
[0059] In another aspect of the present invention, a method for effectively reducing the immunogenicity of urate oxidase is provided, which can effectively reduce the immunogenicity of urate oxidase and improve the stability of urate oxidase in vivo.
[0060] As used herein, the polyethylene glycol-modified urate oxidase is characterized in that the urate oxidase is not particularly limited and may be urate oxidase of any origin and its urate oxidase analogs, representative examples of which include, but are not limited to, those derived from mammals, microorganisms, plants, etc.
[0061] In another preferred embodiment, the urate oxidase and its analogues are derived from mammals, and preferably have the amino acid sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, more preferably SEQ ID NO:1.
[0062] The urate oxidase from different species according to the present invention can be obtained by various methods including, but not limited to, natural extraction, chemical synthesis, genetically engineered recombinant expression, and the like.
[0063] In another preferred example, the bacteria is prepared by constructing a recombinant expression strain using E. coli or yeast as a host, and more preferably, recombinant expression is carried out using E. coli as a host bacterium.
[0064] The urate oxidase described in the present invention can be recombinantly expressed in E. coli to obtain a large amount of urate oxidase, and the expressed urate oxidase can be expressed intracellularly or on the cell membrane, or secreted extracellularly. If necessary, a person skilled in the art can obtain high purity urate oxidase by known methods. Examples of these methods include, but are not limited to, centrifugation, bacteriostatic, salting out, ultrafiltration, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography, and a combination of various other techniques.
[0065] The urate oxidase obtained above can be covalently attached to polyethylene glycol via a linking group using methods known in the art.
[0066] In another preferred embodiment, polyethylene glycol modifies lysine residues on the surface of the spatial structure of urate oxidase in a directionally-directed manner. Urate oxidase is covalently bound to the modifying group (also called active group) of PEG via an amide bond, the modifying group (also called active group) of polyethylene glycol includes, but is not limited to, N-hydroxysuccinimide (NHS), N-hydroxysuccinimide carbonate (SC), N-hydroxysuccinimide acetate (SCM), N-hydroxysuccinimide propionate (SPA), N-hydroxysuccinimide butyrate (SBA), succinic acid N-hydroxysuccinimide (SS), and the blocking group of polyethylene glycol includes, but is not limited to, monomethoxy group, ethoxy group, glucose or galactose sugar, preferably monomethoxy group.
[0067] In another preferred embodiment, the polyethylene glycol is linear or straight chain.
[0068] In another preferred embodiment, the relative molecular weight of the polyethylene glycol is less than 6 KD, preferably between 1 KD and 5 KD, and most preferably 5 KD.
[0069] In another preferred embodiment, the present invention provides a method for preparing a polyethylene glycol-modified urate oxidase, the method having one or more features: (1) The supply molar ratio of urate oxidase to polyethylene glycol for modification is 1:50 to 1:150 (urate oxidase:polyethylene glycol), and preferably, the supply molar ratio modification is 1:55 to 1:95. (2) The binding reaction system is a carbonate buffer, and its modified pH range is 9-11.
[0070] The above-mentioned method for preparing polyethylene glycol-modified urate oxidase uses various purification means to obtain high-purity polyethylene glycol-modified urate oxidase.
[0071] In another preferred embodiment, the modified sample is purified using methods including, but not limited to, molecular sieve chromatography, ion exchange chromatography, hydrophobic chromatography, tangential flow ultrafiltration, or a combination, more preferably molecular sieve chromatography, tangential flow ultrafiltration.
[0072] In another aspect of the present invention, there is provided the above polyethylene glycol-modified urate oxidase and its application, which can achieve the effect of sustained and significant reduction of blood uric acid level in the body, and can be used for the treatment of hyperuricemia and gout.
[0073] Said polyethylene glycol urate oxidase is applied by the drug and its composition for treating chronic hyperuricemia or gout, the main symptoms of said hyperuricemia and gout include, but are not limited to, uric acid nephropathy and gouty arthritis.
[0074] The administration route of the polyethylene glycol urate oxidase includes, but is not limited to, intravenous injection, subcutaneous injection, intramuscular injection, and intraperitoneal injection, and is preferably intravenous injection or intramuscular injection, and more preferably intramuscular injection.
[0075] The polyethylene glycol urate oxidase has lower immunogenicity in the body.
[0076] The polyethylene glycol urate oxidase has low immunogenicity, which means that after intramuscular injection of the polyethylene glycol urate oxidase into the human or animal body, the body does not produce antibodies against the polyethylene glycol molecule, or produces antibodies against the polyethylene glycol molecule with low titer, and does not produce antibodies against urate oxidase.
[0077] Said polyethylene glycol urate oxidase has a longer half-life in the body after intramuscular injection, and the efficacy of lowering the uric acid level in the body.
[0078] According to the embodiment of the present invention, under the premise of ensuring the maximum activity of the enzyme, the polyethylene glycol-modified urate oxidase of the present invention can greatly improve the stability of urate oxidase in vivo, reduce immunogenicity, and the efficacy in vivo after intramuscular injection can reach the same efficacy in vivo after injection of similar drugs already on the market.Therefore, the polyethylene glycol-modified urate oxidase of the present invention and the pharmaceutical composition containing the polyethylene glycol-modified urate oxidase can be administered when treating or preventing hyperuric acid-related diseases.
[0079] The term "administration" as used herein refers to introducing a predetermined amount of a substance into a patient in a suitable manner. The polyethylene glycol-modified urate oxidase of the present invention can be administered by any common route as long as it can reach the desired tissue. Various methods of administration include peritoneal, intravenous, intramuscular, subcutaneous, dermal, oral, topical, nasal, pulmonary and rectal, as desired, but the present invention is not limited to these listed administration methods. In addition, the pharmaceutical composition of the present invention can be administered using a specific device that delivers the active ingredient to the target cell.
[0080] The frequency and dosage of administration of the pharmaceutical composition of the present invention can be determined by several related factors, including the type of disease being treated, the route of administration, the age, sex, weight, and severity of the patient, and the type of drug as the active ingredient.
[0081] The term "therapeutically effective amount" refers to an amount of a compound sufficient to significantly improve a certain symptom associated with a disease or disorder, i.e., an amount that provides a therapeutic effect for a given disorder and administration regimen. For example, in chronic hyperuricemia or gout treatment, a drug or compound that reduces, prevents, delays, inhibits or blocks any symptoms of the disease or disorder is effective for treatment. A therapeutically effective amount of a drug or compound does not necessarily cure the disease or disorder, but provides treatment for the disease or disorder, such that an individual's onset of the disease or disorder is delayed, inhibited or prevented, the symptoms of the disease or disorder are alleviated, the duration of the disease or disorder is changed, e.g., the disease or disorder is less severe, or recovery is accelerated.
[0082] The term "treatment" refers to obtaining a desired pharmacological and / or physiological effect. The effect may be preventive in that it completely or partially prevents a disease or its symptoms, and / or may be therapeutic in that it partially or completely cures a disease and / or side effects due to the disease. As used herein, "treatment" covers the treatment of a disease (mainly referring to hyperuric acid-related diseases) in a mammal, particularly a human, and includes (a) preventing the disease in an individual who is susceptible to the disease but has not yet been diagnosed with the disease, (b) inhibiting the disease, such as slowing the progression of the disease, or (c) alleviating the symptoms associated with the disease. As used herein, "treatment" includes any drug or compound administered to an individual to treat, cure, alleviate, ameliorate, reduce or inhibit a disease in an individual, including, but not limited to, administering a polyethylene glycol-modified urate oxidase as described herein to an individual in need thereof.
[0083] According to embodiments of the present invention, the polyethylene glycol-modified urate oxidase or pharmaceutical composition of the present invention may be used in combination with conventional treatment methods and / or therapies, or may be used separately from conventional treatment methods and / or therapies. When administered in a combination therapy with other drugs, the polyethylene glycol-modified urate oxidase or pharmaceutical composition of the present invention may be administered to an individual sequentially or simultaneously. Alternatively, the pharmaceutical composition of the present invention may include a combination of the polyethylene glycol-modified urate oxidase of the present invention, a pharma- ceutical acceptable carrier or a pharma-ceutical acceptable excipient, and other therapeutic or prophylactic agents known in the art.
[0084] The term "average degree of modification" refers to the number of PEGs attached to each uricase monomer.
[0085] In the present specification, unless otherwise specified, the expression "an amino acid site has a PEG modification" means that in the corresponding polypeptide conformation, a PEG molecule covers the amino acid site, so that at least a part of the group at the amino acid site is not exposed. Those skilled in the art can understand that whether a specific amino acid site is modified by a PEG molecule can be determined by conventional technical means, for example, by referring to the methods listed in the part "Detection of Polyethylene Glycol Modification Site" in Example 3 of the present application. In short, the method includes the steps of: 1) digesting non-polyethylene glycolated and polyethylene glycolated urate oxidase with one or more enzymes, for example, single digestion with Lys-C or Trypsin, or double digestion with Lys-C and Trypsin; 2) separating the digested fragments by high performance liquid chromatography, and creating chromatograms, i.e., peptide maps, of non-polyethylene glycolated and polyethylene glycolated urate oxidase; and 3) comparing the differences between the peptide maps of non-polyethylene glycolated and polyethylene glycolated urate oxidase, and combining with a predetermined internal standard peptide segment to determine the relative reduction or disappearance of the peptide segment peak where the specific amino acid site of polyethylene glycolated urate oxidase is located, and further determining whether the specific amino acid site in the peptide segment is modified by PEG. Specifically, in Example 3 of the present application, the relative reduction or disappearance of the peak area of the peptide segment where the specific amino acid site is located can be calculated by the following formula: P(%)=(A2-A1) / A2×100%, A1 = A0 × t where A0 is the actual measured peak area of the peptide segment in which the specific amino acid site of the modified protein under test is located, and t is the average peak area ratio of the internal reference peptide segment of the PHC peptide map and the peptide map of the modified protein under test; P (%) indicates the relative percentage of decrease or disappearance of the peak area of the peptide segment in which the specific amino acid site is located, A2 is the peptide segment peak area of the peptide segment in which the specific amino acid site is located in the PHC peptide map, and A1 is the peak area of the peptide segment in which the specific amino acid site is located in the peptide map of the modified protein being tested after conversion by internal reference.
[0086] It should be understood that within the scope of the present invention, each of the above technical features of the present invention can be combined with various technical features specifically described below (e.g., in the Examples), thereby constituting a new or preferred technical solution, which can be more clearly understood by referring to the following examples. Due to the limited length of the specification, the above examples are for illustrative purposes only and are not intended to limit the present invention.
[0087] Hereinafter, the embodiments of the present invention will be described in detail, and examples of the embodiments are shown in the drawings. The embodiments described below with reference to the drawings are illustrative and are used to interpret the present invention, but should not be understood as limiting the present invention.
[0088] Example 1 Preparation of recombinant urate oxidase
[0089] 1.1 Construction of uricase expression gene and expression plasmid Based on E. coli codon usage bias data, combined with factors such as codon preference and GC content, a cDNA sequence of uricase protein (code name: PHC) (SEQ ID NO: 1) is designed, and the whole gene is synthesized and named pUC-57-PHC plasmid. Nde I and BamH I are used as the target gene insertion sites, and pET-30a plasmid is used as the expression vector (pET-30a-PHC).
[0090] 1.2 Transformation of expression plasmids into bacterial host cells The expression vector pET-30a-PHC is introduced into E. coli BL21(DE3) by the CaCl2 method, the resistance of Kanamycin is screened, high-expressing clones are screened, and the original seed bank strain (E3B) is preserved. These steps are carried out according to common methods in the field of molecular biology.
[0091] 1.3 Preparation of recombinant urate oxidase The transformed engineering strain was fermented and expressed in a fermenter, and the controlled conditions were initially 30°C, pH about 7.2, and OD 600 Culture the cells until the temperature reaches 30°C or higher, add IPTG to 0.5 mmol / L, and continue induction for 3 h or more to allow accumulation of urate oxidase. Collect the cells by centrifugation and then store at -15°C or lower.
[0092] Take the frozen bacteria and suspend them in 25 mmol / L Tris, 5 mmol / L EDTA buffer, the suspension ratio is 1:10 (W / V). After the bacterial cells are crushed under high pressure, the urate oxidase precipitate is collected by centrifugation, the precipitate is washed once with 50 mmol / L NaHCO3, and then the concentrated uricase precipitate is suspended in 100 mmol / L Na2HCO3 (pH 9.7-10.3) buffer, the suspension ratio is 1:50 (W / V), and dissolved by stirring overnight at room temperature, and then the supernatant is collected by centrifugation.
[0093] The urate oxidase was further purified by several chromatographic steps, with SDS-PAGE detection purity of 95% or more, purity of 95% or more by Superdex 200 column, free of aggregate form, protein concentration was measured using the Lowry method, and activity of urate oxidase was measured using a spectrophotometer, with 1 unit (U) of enzyme activity defined as the amount required to transform 1 μmol of uric acid per minute under optimal reaction temperature of 37°C and optimal pH of 9.0 buffer conditions.
[0094] Example 2 Preparation of polyethylene glycol-modified urate oxidase 5KD molecular weight N-propionate succinimide PEG (5K-PEG-SPA) is dissolved in 200mmol / L PEG solution with 2mmol / L HCl, and after dissolution, the molar ratio of urate oxidase to 5K-PEG-SPA is calculated according to the monomer form at 1:55-1:95 molar ratio (urate oxidase:5K-PEG-SPA), that is, the molar ratio of urate oxidase to 5K-PEG-SPA is calculated according to the monomer form, that is, the molar ratio of urate oxidase to 5K-PEG-SPA in the monomer form is added to a carbonate buffer solution with a carbonate concentration of 0.1-0.3mol / L and a pH of 10.0 in which urate oxidase is dissolved, and PEG and urate oxidase undergo a binding reaction, which should be reacted by stirring for 60 minutes or more under conditions of 5-30°C until the degree of PEG binding does not change with time. After the reaction is completed, the unmodified PEG and by-products are removed from the reaction by ultrafiltration and / or chromatography. The modified by-products are separated and removed using an appropriate molecular sieve chromatography medium, and finally, the 5K modified PEGylated urate oxidase (codenamed PU5) is obtained by sterile filtration.
[0095] Example 3 Characterization of polyethylene glycol-modified urate oxidase
[0096] 3.1 Average modification degree and enzyme activity detection The protein concentration is measured by the Lowry method, and the activity of polyethylene glycol urate oxidase is measured by a spectrophotometer. The maximum ultraviolet absorption wavelength of the uricase substrate uric acid is 293 nm, and the maximum ultraviolet absorption wavelength of the product allantoin is 224 nm. Within a certain concentration range, the absorption value of uric acid at 293 nm is proportional to its concentration, and the quantitative measurement of uric acid can be performed by the spectrophotometer method. The specific process is as follows: using a UV-visible spectrophotometer, adjust the wavelength to 293 nm, turn on the water bath circulation system of the instrument to keep the temperature at 37 ° C. Sodium tetraborate buffer is used as the blank control to correct the zero point, and 2.95 ml of substrate reaction solution (0.1 mol / L sodium tetraborate, 100 μmol / L uric acid, pH 9.5, preheated to 37 ° C) is taken and placed in a quartz cuvette, and then 50 μl of the test substance is added and mixed quickly, and the absorption value is measured at 293 nm. The change in absorbance at 293 nm was continuously measured, and the decomposition concentration of uric acid was calculated according to C=A / εL (A is the absorbance value at 293 nm of a specific concentration of uric acid, ε is the molar absorption coefficient of uric acid, L is the light path of the cuvette, and C is the molar concentration of uric acid). The enzyme activity was calculated by defining the amount of enzyme required to convert 1 μmol of uric acid into allantoin per minute at the optimal reaction temperature of 37°C and the optimal reaction pH of 9.5 as one activity unit (U).
[0097] SEC-HPLC tandem UV / RI (combination of ultraviolet and refractive index detector) is used to detect the average modification degree of polyethylene glycol urate oxidase. According to protein, it has a maximum absorption peak at 280nm of ultraviolet, and PEG has no absorption at this wavelength, and at the same time, according to the differential refractive index detector, the absorption value of protein and PEG within a certain range is proportional to its various concentrations. Therefore, the respective contents of PEG and protein moieties in polyethylene glycol urate oxidase can be obtained by the external standard of PEG reference material and PHC physical and chemical reference material, and further, the number of PEG molecules on each urate oxidase monomer, that is, the average modification degree, can be obtained by the following calculation method.
[0098] The average degree of modification of PEG-urate oxidase=(relative molecular weight of urate oxidase subunit×amount of PEG in sample) / (relative molecular weight of PEG×amount of protein in sample).
[0099] The SEC-HPLC-UV / RI detection patterns of the PHC physical and chemical reference material, PEG reference material, and PU5 modified product are shown in Figures 1 to 5.
[0100] The enzyme activity and average modification degree of the polyethylene glycol urate oxidase obtained under different feeding ratios in Example 2 are shown in Table 1. [Table 1]
[0101] As can be seen from Table 1, the polyethylene glycol urate oxidase of the present application is stable with an average modification degree of 11 or more, and the enzyme activity is higher than that of unmodified urate oxidase, and the enzyme activity retention rate is higher, the enzyme activity is not decreased, but is improved, and the enzyme activity is relatively stable. This is completely different from the commercially available drug Krystexx (pegloticase), and according to the contents disclosed in Mountain View patent (CN1264575C, Figure 2A-Figure 3B) and the general knowledge of those skilled in the art, the enzyme activity is significantly decreased with the increase in the degree of modification with 5kD PEG. However, unexpectedly, the polyethylene glycol uricase obtained in the present application has an average modification degree of more than 11, and the enzyme activity does not change significantly compared to that of the unmodified case. Therefore, the polyethylene glycol urate oxidase of the present application has a higher average modification degree of polyethylene glycol compared to commercially available drugs, and also achieves an unexpected technical effect in terms of the retention of enzyme activity. The inventors presume that this may be caused by differences in the degree or site of PEG modification of polyethylene glycol urate oxidase.
[0102] The inventors have modified the proteins of SEQ ID NO:2-7 to obtain the same technical effect, ie, to obtain PEGylated urate oxidase without substantial loss of enzymatic activity when the degree of 5 kd modification is greater than 11.
[0103] 3.2 Detection of polyethylene glycol modification sites In the following steps, the inventors detect the modification sites of the urate oxidase obtained in Example 2.
[0104] The PEG modification site of the polyethylene glycol-modified urate oxidase is determined by digesting the non-polyethylene glycol-modified and polyethylene glycol-modified urate oxidase with one or more enzymes, and then performing chromatographic detection to obtain a chromatogram, i.e., confirming the peptide map. The non-polyethylene glycol-modified and polyethylene glycol-modified urate oxidase can be digested by single digestion (Lys-C or Trypsin) and / or double digestion (Lys-C and Trypsin in combination). The digested fragments are separated by a reversed-phase column, and the modification site of the polyethylene glycol-modified urate oxidase is determined by comparing the disappearance or reduction ratio of the peptide segment with the internal reference peptide segment correction.
[0105] The principle of modification site analysis in trypsin and Lys-C double digestion quality peptide map is as follows: Lys-C can specifically digest the C-terminus of lysine (K), and trypsin uses the basic amino acid-arginine (R) and lysine (K) as the digestion site to specifically digest its C-terminal peptide bond. By comparing the changes of each corresponding peptide segment before and after digestion with PHC and PU5, and combining the internal standard peptide segment, the relative percentage of reduction or disappearance of PEG-modified peptide segments can be analyzed and confirmed. Through the relative percentage of reduction or disappearance of peptide segments, it can be determined whether the lysine site on the peptide segment is modified by PEG and the percentage of modification. It should be noted that PEG modification is a heterogeneous modification, and if a certain site has a high percentage of modification, the site can be considered to be modified.
[0106] Specifically, it is as follows: (1) Sample treatment: Urate oxidase and polyethylene glycolated urate oxidase are dissolved and diluted to 1 mg / ml in digestion buffer (25 mmol / L Tris-HCl, 20% acetonitrile, pH 9.0), and 100 μl of each is taken, and 2 μl of Lys-C is added and digested at 37° C. for 4 hours. That is, the solution is transferred to a pancrelipase reaction tube (1:100 ratio), digested at 37° C. for 2 hours, reacted with 4 μl of TCEP reducing solution for 30 minutes, and the reaction is stopped by adding 10 μl of 1 mol / L hydrochloric acid solution. (2)Analysis conditions Equipment: Thermo Ultimate 3000 HPLC and MSQ Plus, Chromatography column: Tsukiasahi Welch Materials μltimate (R) XB-C 18 (4.6mm x 250mm, 5μm), Analysis conditions: Solution A (aqueous solution containing 0.1% TFA), Solution B (acetonitrile solution containing 0.1% TFA), Gradient: 0-70min, B 3-70%, LC detection wavelength: 214 nm. Ion source: ESI, Ion type: cation, Cone voltage: 50V, Scanning range: 300-2000Da, Scanning time: 1S, Post-column split flow approximately 0.3 ml / min. A sample volume of 100 μl is injected and the chromatogram is recorded. (3) Result processing: The chromatograms (peptide maps) of urate oxidase and pegylated urate oxidase are compared to calculate the relative percentage of area reduction of the different peptide segments. (4) The experimental results are shown in Tables 2 to 5 and Figures 6 to 7. [Table 2] JPEG2024037877000003.jpg69170 [Table 3] JPEG2024037877000005.jpg255170JPEG2024037877000006.jpg192170
[0107] The calculation method for the reduction rate of the PU5 peptide segment peak area is as follows: Calculate the corresponding PU5 peptide segment peak area at the same concentration of PU5 and PHC by the following formula: A1 = A0 × t A1 is the peak area of the PU5 peptide segment after conversion of the two internal reference peptide segments, A0 is the actual measured peak area of the PU5 peptide map peptide segment, and t is the average value of the peak area ratio of the PHC peptide map and the PU5 peptide map in the internal reference peptide segments numbered T30 and T31, i.e., 0.588. [Table 4]
[0108] The relative percentage of the reduction in the peak area of a peptide segment in the PU5 peptide map can be calculated by the following formula: P(%)=(A2- A1) / A2×100% where A2 is the peptide segment peak area of a peptide segment in the PHC peptide map, and A1 is the PU5 peptide segment peak area of the peptide segment after internal referencing reduction.
[0109] [Table 5]
[0110] As can be seen from the protein sequence analysis (SEQ ID NO:1) in this example, the potential sites for modification of urate oxidase are T 1 , K 3 , K 4 , K 17 , K 21 , K 30 , K 35 , K 48 , K 49 , K 66 , K 74 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 155 , K 158 , K 169 , K 179 , K 190 , K 215 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 It has 31 sites such as:
[0111] As can be seen from the analysis of the modification sites of the polyethylene glycol-modified urate oxidase obtained in Example 2, as shown in Tables 2, 3, 4, 5 and FIG. 6, after digestion with PU5, the sites that disappear in more than 90% of the peptide segments are K 3 , K 4 , K 35 , K 97 , K 112 , K 116 , K 120 , K 152 , K 222 , K 266 , K 285 After PU5 digestion, the sites that disappear within 80% to 90% of the peptide segment are K 76 , K 231 and in PU5, all of these sites are modified.
[0112] At the same time, the inventors have found that the modification sites of the polyethylene glycol-modified urate oxidase of the present application are more and significantly different than those of commercially available drugs. For example, through a single digestion, the polyethylene glycol-modified urate oxidase of the present application has a higher K 30 , K 35 , K 222 and K 231 The disappearance rate of the peptide segment where these four sites are located is more than 80%, and by analyzing Krystexx (pegloticase), a similar drug available on the market, the disappearance rate of the peptide segment where these four sites are located is almost not observed. 30 , K 35 , K 222 and K 231The inventors found that the modification rate at the four sites is much lower than that of the polyethylene glycol-modified urate oxidase of the present application. In addition, the immunogenicity of the polyethylene glycol-modified urate oxidase of the present application is significantly reduced compared with that of commercially available drugs, and the inventors presume that this is related to the number of modification sites and the difference in the modification sites. Due to the different modification sites and modification degrees, the protection of the immunogenic sites of the enzyme in the body and the exposure of the active center of the enzyme are different, which may cause different biological properties of the modified enzyme in the body.
[0113] The following provides a detailed description of the in vivo animal drug evaluation of the polyethylene glycol-modified urate oxidase (PU5) of the present application. The pegloticase used in the experiment refers to a similar drug that is commercially available, with the lot number 5085B.
[0114] Example 4 Study on the pharmacodynamics of polyethylene glycol urate oxidase in vivo
[0115] 4.1. Evaluation of the efficacy of polyethylene glycol urate oxidase in rat models Potassium oxonate drinking water was used in combination with high uric acid diet to induce a chronic hyperuricemia model in rats, and the therapeutic effect of polyethylene glycol urate oxidase (PU5) on chronic hyperuricemia in rats was evaluated.
[0116] Select 40 model rats and randomly divide them into 4 groups, namely model group, polyethylene glycolated uricase low dose group (0.3mg / kg), polyethylene glycolated uricase medium dose group (1.0mg / kg), polyethylene glycolated uricase high dose group (3.0mg / kg), 10 rats in each group, and select another 10 normal SD rats as blank control group. The test is modeled for 5 consecutive weeks, and after 1 week of modeling, intramuscular administration is started, and administered once a week, for 4 consecutive weeks. The serum uric acid, serum urea nitrogen, and serum creatinine levels of the rats before administration and 7 days after each administration are detected respectively, and the histological changes of the rat kidney are observed after the test.
[0117] As shown in the results of Figure 8, on the 7th, 14th, 21st, 28th and 35th days after modeling, compared with the blank control group, the blood uric acid levels of the model control group were all significantly increased, and after 7 days of modeling, the serum urea nitrogen, creatinine and uric acid of the rats in the model group were 2.73 times, 2.40 times and 7.83 times that of the rats in the blank group, respectively. From the perspective of renal pathology (as shown in Figure 9), the scores of renal tubule dilation, necrosis, inflammation and fibrosis of the model control group were all significantly increased, and at the same time, the quantity of urate crystals was also significantly increased. Both medium and high doses of the test substance polyethylene glycolated uricase significantly reduced serum uric acid levels, showing a dose-related relationship, and the mean blood uric acid level of the medium dose group was maintained at 303.80-660.60 μmol / L and the mean blood uric acid level of the high dose group was maintained at 153.70-403.40 μmol / L during 14-35 days, and compared with the model group, the range of blood uric acid reduction in the medium dose group was 34.46-67.94%, and the range of blood uric acid reduction in the high dose group was 65.67-83.78%. Compared with the model control group, each administration group of polyethylene glycolated uricase has a significant improving effect on renal tubular dilatation, renal necrosis and inflammation.
[0118] 4.2. Evaluation of single-dose administration of polyethylene glycol urate oxidase in rats Thirty-six SD rats were taken, half of which were male and half of which were female, and randomly divided into six groups (shown in Table 6), namely, the commercially available Pegloticase intravenous injection group, the intramuscular injection group, the polyethylene glycol urate oxidase intravenous injection group, and the polyethylene glycol urate oxidase low, medium, and high (0.5, 1.0, 2.0 mg / kg) dose intramuscular injection group, with the specific dosing schedule and doses shown in Table 6. PK and PD were detected by blood sampling from the jugular vein.
[0119] [Table 6]
[0120] 4.2.1. Comparison of pharmacokinetics Before administration to SD rats, the serum drug concentration levels of all individuals were lower than the lower limit of quantification (LLOQ: 312.500ng / mL). After a single intramuscular injection of 0.5, 1.0, and 2.0mg / kg polyethylene glycol uricase injection (PU5) within the range of 0-168h (0-7 days), the serum drug concentrations were dose-dependent, and the overall levels increased with increasing dose. After 168h, the blood concentration of the pegloticase intramuscular administration group was lower than the lower limit of quantification, and the blood concentration of the PU5 intramuscular administration group could be maintained for more than 240h.
[0121] After administration, the internal C of female and male SD rats in each group was measured using intravenous and intramuscular injection of 1.0 mg / kg Pegloticase, intravenous injection of 1.0 mg / kg polyethylene glycolated uricase, and intramuscular injection of 0.5, 1.0, and 2.0 mg / kg polyethylene glycolated uricase. max (C 5min ) ratios were in the range of 0.75–0.99, and the AUC last The ratios were in the range of 0.54–0.94, and the AUC 0-∞ The ratios were in the range of 0.58 to 0.97. This indicates that there is no significant difference in the exposure levels between the sexes of SD rats to Pegloticase and polyethylene glycolated uricase (PU5) injections.
[0122] However, when SD rats were administered the same dose (1.0 mg / kg) of the commercially available drug Pegloticase, the AUC last was 426.48 ± 65.34, and the AUC last The AUC last was 565.61 ± 161.60, and the AUC last The AUC of PU5 was 337.86 ± 227.34 under the same dose and similar administration conditions. last is more expensive than the over-the-counter drug Pegloticase.
[0123] When SD rats were administered the same dose (1.0 mg / kg) of the commercially available drug Pegloticase, the t 1 / 2 (h) was 49.51 ± 8.12, and t 1 / 2 (h) was 55.21 ± 13.50. The t 1 / 2 (h) was 86.12 ± 33.82, and t 1 / 2 (h) is 60.45±21.37. Under the same dose and similar administration conditions, the t 1 / 2 (h) is longer than the commercially available drug Pegloticase.
[0124] The pharmacokinetic results are shown in Tables 7 to 12 and Figures 10 to 12. [Table 7] JPEG2024037877000011.jpg74170
[0125] [Table 8] JPEG2024037877000013.jpg194170
[0126] [Table 9] JPEG2024037877000015.jpg54170
[0127] [Table 10]
[0128] [Table 11]
[0129] [Table 12] JPEG2024037877000019.jpg248170
[0130] 4.2.2. Comparison of availability in the body (uric acid) After a single intramuscular injection of 0.5, 1.0, or 2.0 mg / kg polyethylene glycol uricase injection, the uric acid concentration remained at a low level 1 and 3 days after administration, and the uric acid level of each dose group began to recover 7 days after administration, and the higher the dose, the longer the time that uric acid remained at a low level in the body. Compared with the intravenous injection group of the same dose, the time that serum uric acid remained at a low level in the PU5 intravenous injection group was longer than that of the pegloticase intravenous injection group. Compared with the intramuscular injection group of the same dose, the time that serum uric acid remained at a low level in the PU5 intramuscular injection group was longer than that of the pegloticase intramuscular injection group. Compared with the intramuscular injection group of the same dose, the time that serum uric acid remained at a low level in the PU5 intravenous or intramuscular injection group was longer than that of the pegloticase intravenous or intramuscular injection group, that is, the time that PU5 remained at a low level in the body was longer than that of the pegloticase intravenous or intramuscular injection group. The results are shown in Figure 13.
[0131] 4.3. Evaluation of multiple administrations of polyethylene glycol urate oxidase to rats In this study, the rats were divided into 4 groups: a group that received intravenous injections of the commercially available drug Pegloticase, a group that received intramuscular injections, a group that received intravenous injections of polyethylene glycolated uricase injection (PU5), and a group that received intramuscular injections. Each group had 8 rats, half of which were male and half were female, for a total of 32 SD rats. The group that received intravenous injections of Pegloticase and polyethylene glycolated uricase injection used intravenous injections, while the group that received intramuscular injections of Pegloticase and polyethylene glycolated uricase injection used intramuscular injections. The dosage was 1.0 mg / kg for both groups. The drugs were administered once a week for a total of 4 consecutive doses.
[0132] As can be seen from the analysis of the results, Pegloticase and polyethylene glycolated uricase injections of 1.0mg / kg were administered intravenously / intramuscularly to SD rats multiple times. No drug-related abnormal changes were observed in the general condition of the rats.
[0133] 4.3.1 Detection of anti-PEG antibodies After four consecutive doses in SD rats, anti-PEG and anti-PHC antibodies were not detected in any individual animals before the first dose, and anti-PHC antibodies were not detected in any animals after the end of the dose, and anti-PEG antibodies were detected in the pegloticase intravenous and intramuscular injection groups, and the polyethylene glycolated uricase injection intravenous and intramuscular injection groups, with the positive results being 3 / 8, 1 / 8, 1 / 8, and 1 / 8, respectively. PEG immunohistochemical examination revealed that the spleen, liver, and kidney of the pegloticase intravenous and intramuscular injection groups showed weak positive expression of PEG. No positive expression of PEG was found in the polyethylene glycolated uricase injection intravenous and intramuscular injection groups, and the results are shown in Table 13.
[0134] From the above analysis, it can be seen that the antibodies generated by PU5 and pegloticase are not antibodies against the urate oxidase moiety, but mainly antibodies against the PEG moiety, which indicates that both can effectively block the immunogenic sites of urate oxidase. The generation of PEG antibodies may cause some side effects in the body, and according to the results in Table 13, the immunogenicity of PU5 of this application is lower than that of the commercial product pegloticase.
[0135] As can be seen from the results of PEG antibody and PEG immunohistochemistry, both PU5 and pegloticase were superior in the intramuscular administration group compared with the intravenous administration group, anti-PEG antibodies generated in the intravenous administration group and PU5 were superior to pegloticase, and anti-PEG antibodies generated in the intramuscular administration group and PU5 were superior to pegloticase.
[0136] [Table 13]
[0137] 4.3.2 Pharmacokinetic detection After multiple intravenous and intramuscular injections of Pegloticase and polyethylene glycolated uricase injections into SD rats, there was no significant difference in the main pharmacokinetic parameters of animals in each group. After four consecutive doses, the two drugs accumulated slightly in the rats' bodies.
[0138] The same dose (1.0mg / kg) of the commercially available drug Pegloticase was injected intravenously / intramuscularly multiple times into SD rats. After the first dose, the absolute bioavailability in the rats was 51.35%, and after the final dose, the absolute bioavailability in the rats was 45.98%. The same dose (1.0mg / kg) of polyethylene glycolated uricase injection was injected intravenously / intramuscularly multiple times into SD rats. After the first dose, the absolute bioavailability in the rats was 58.29%, and after the final dose, the absolute bioavailability in the rats was 52.60%.
[0139] 4.3.3 Comparison of availability in the body (uric acid) SD rats were given 1.0mg / kg of Pegloticase and polyethylene glycolated uricase injections intravenously and intramuscularly four times (once a week), and after each injection, serum uric acid levels remained low, with the Pegloticase intramuscular injection group recovering 14 days after the final injection, and the remaining groups recovering 18 days after the final injection. Compared with the same dose of the commercially available drug Pegloticase, the retention times of the two drug intravenous injection groups were relatively consistent, and the retention time of the polyethylene glycolated uricase intramuscular injection group was longer than that of the commercially available drug, which means that the therapeutic effect of intramuscular administration of PU5 is superior to that of Pegloticase.
[0140] The results are shown in Tables 14 to 17 and Figs. 14 to 19.
[0141] [Table 14] JPEG2024037877000022.jpg186170
[0142] [Table 15] JPEG2024037877000024.jpg251170JPEG2024037877000025.jpg250170JPEG2024037877000026.jpg100170
[0143] [Table 16] JPEG2024037877000028.jpg80170
[0144] In the description of this specification, the description of the reference terms such as "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" means that the specific features, structures, materials, or characteristics described in the combination of the embodiment or examples are included in at least one embodiment or example of the present invention. In this specification, exemplary descriptions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described can be combined in any suitable manner in any one or more embodiments or examples. It should be noted that, unless inconsistent, a person skilled in the art can combine and combine different embodiments or examples and features of different embodiments or examples described herein.
[0145] Although embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are illustrative and should not be construed as limiting the present invention, and that those skilled in the art may make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.
Claims
1. A method for producing polyethylene glycol-modified urate oxidase, comprising the steps of: subjecting urate oxidase to a coupling reaction with polyethylene glycol; providing the polyethylene glycol in the form of an acidic solution; and obtaining the polyethylene glycol-modified urate oxidase at a molar ratio of 1:(50-150).
2. 2. The method according to claim 1, wherein the molar ratio of urate oxidase to polyethylene glycol is 1:(55-110).
3. 2. The method according to claim 1, wherein the molar ratio of urate oxidase to polyethylene glycol is 1:(56-94).
4. 2. The method of claim 1, wherein the acidic solution is an acidic solution comprising an inorganic acid.
5. The inorganic acid is 5. The method according to claim 4, characterized in that the acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid, hydroiodic acid, nitric acid, persulfuric acid, boric acid, dichromic acid, silicic acid, chromic acid and thiocyanic acid.
6. 2. The method according to claim 1, wherein the concentration of hydrogen ions in the acidic solution is 1 to 5 mmol / L.
7. The acid solution comprises hydrochloric acid, sulfuric acid, or glacial acetic acid; 2. The method according to claim 1, wherein the concentration of the acid in the acidic solution is 1 to 5 mmol / L.
8. 2. The method according to claim 1, wherein the concentration of the polyethylene glycol in the acidic solution is 100 to 300 mmol / L.
9. The polyethylene glycol molecular weight is 6 KD or less; or The polyethylene glycol has a monomethoxy or hydroxyl group, or The polyethylene glycol is linear or branched; or The polyethylene glycol and urate oxidase are coupled via an amide bond; or The polyethylene glycol is a modified polyethylene glycol, and the modifying group of the modified polyethylene glycol is 2. The method according to claim 1, characterized in that the hydroxysuccinimide is selected from at least one of N-hydroxysuccinimide, N-hydroxysuccinimide carbonate, N-hydroxysuccinimide acetate, N-hydroxysuccinimide propionate, N-hydroxysuccinimide butyrate, N-hydroxysuccinimide succinate and p-nitrophenyl carbonate, preferably N-hydroxysuccinimide propionate.
10. The coupling reaction is carried out in a carbonate buffer solution; 2. The method of claim 1, wherein the carbonate buffer solution has a pH of 9 to 11.
11. The method of claim 1, wherein the coupling reaction is carried out at 5 to 30° C. for at least 60 minutes.
12. As the amino acid site of the urate oxidase, 1 , K 3 , K 4 , K 30 , K 35 , K 76 , K 79 , K 97 , K 112 , K 116 , K 120 , K 152 , K 179 , K 222 , K 231 , K 266 , K 272 , K 285 , K 291 , K 293 At least 11 of the above have PEG modifications; The method of claim 1, characterized in that the amino acid site is localized to the amino acid sequence shown in SEQ ID NO:
1.
13. The urate oxidase has an amino acid sequence as set forth in SEQ ID NO: 1-7; or having a polypeptide having at least 70% identity to SEQ ID NO: 1-7; or 2. The method of claim 1, comprising a polypeptide having one or more amino acid substitutions, deletions and / or additions compared to SEQ ID NOs: 1-7.
14. The method according to claim 12, wherein the urate oxidase has an amino acid sequence represented by SEQ ID NO: 1 to 4.
15. The polyethylene glycol-modified urate oxidase is K 30 , K 35 , K 222 and K. 231 At least one of the four amino acid sites is PEGylated, The method according to any one of claims 1 to 14, characterized in that the amino acid site is localized to the amino acid sequence shown in SEQ ID NO:
1.
16. The method according to any one of claims 1 to 14, wherein a relative ratio of a reduction in a peak area having at least 11 predetermined peptide segments in the peptide map of the polyethylene glycol-modified urate oxidase compared to a peptide map of the urate oxidase not modified with polyethylene glycol is 75% or more.
17. The urate oxidase has an amino acid sequence as shown in SEQ ID NO: 1, and the peptide map of the polyethylene glycol modified urate oxidase is compared with the peptide map of the urate oxidase not modified with polyethylene glycol in the following table: and the corresponding relative percentages of peak area reduction are shown in
18. The urate oxidase has the amino acid sequence shown in SEQ ID NO: 1, 3 , K 4 , K 35 , K 97 , K 112 , K 116 , K 120 , K 152 , K 222 , K 266 , K 285 , K 76 , K 231 The method of claim 15, characterized in that the carboxyl group has a PEG modification at position 15.
19. The peptide map of the polyethylene glycol-modified urate oxidase is compared with the peptide map of the urate oxidase not modified with polyethylene glycol, and shows that the amino acid position K 3 , K 4 , K 35 , K 97 , K 112 , K 116 , K 120 , K 152 , K 222 , K 266 , K 285 The peak area reduction of the peptide segment in which the amino acid position K is located is 90% or more, 76 , K 231 The method according to claim 18, characterized in that the peak area reduction of the peptide segment in which is located is 80-90%.
